Abstract
Along with the comprehensive data concerning our institutional experience on the use of rituximab for treatment of non-Hodgkin's lymphoma, we describe the first case of molecular remission induced by the chimeric anti-CD20 monoclonal antibody in a diffuse large cell lymphoma patient.
Original language | English |
---|---|
Pages (from-to) | 437-438 |
Number of pages | 2 |
Journal | Haematologica |
Volume | 85 |
Issue number | 4 |
Publication status | Published - 2000 |
Keywords
- Aggressive lymphoma
- Molecular remission
- Rituximab
ASJC Scopus subject areas
- Hematology